ライフサイエンスコーパス: first-line treatment

1 ely managed with intramuscular adrenaline as first line treatment.

2 ernational guidelines recommend their use as first line treatment.

3 receive a triple DAA combination regimen as first-line treatment.

4 oblastoma patients resistant to the standard first-line treatment.

5 significant treatment-related toxicities of first-line treatment.

6 rease) as oral targeted therapies become the first-line treatment.

7 re more prevalent in the rotating arm during first-line treatment.

8 etastatic NETs and disease progression after first-line treatment.

9 re EGFR-blocking antibodies are approved for first-line treatment.

10 ing ART, in line with nationally recommended first-line treatment.

11 eak and PLPS and, thus, should be considered first-line treatment.

12 best tolerated of the three and the standard first-line treatment.

13 erapies leaves uncertainty regarding optimal first-line treatment.

14 symptomatic relapses after the completion of first-line treatment.

15 vention for mania, is no longer considered a first-line treatment.

16 urvival in patients with SCLC who respond to first-line treatment.

17 to recommendations for therapy options after first-line treatment.

18 y, and should be considered as an option for first-line treatment.

19 d time to disease progression after starting first-line treatment.

20 nd the responsiveness of MDR tuberculosis to first-line treatment.

21 with high-potency topical corticosteroids as first-line treatment.

22 over 4 days with mesna and pegfilgrastim) as first-line treatment.

23 een revised to include behavioral therapy as first-line treatment.

24 evelop recurrent or refractory disease after first-line treatment.

25 ne-kinase inhibitors had not been given as a first-line treatment.

26 is a safe alternative but is rarely used as first-line treatment.

27 (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment.

28 e plus oral azithromycin) is the recommended first-line treatment.

29 esponse to chemotherapy and immunotherapy as first-line treatments.

30 ation therapies (ACTs) are used worldwide as first-line treatment against confirmed or suspected Plas

31 d isolates had antimicrobial resistance to a first-line treatment agent.

32 Resistance to first-line treatment agents in patients with Salmonella

33 7 patients, 32 were receiving tagraxofusp as first-line treatment and 15 had received previous treatm

34 All patients were refractory to first-line treatment and harbored a BRAF(V600E) mutation

35 ould be proposed as the standard of care for first-line treatment and rituximab-based regimens for se

36 aliplatin with or without bevacizumab in the first-line treatment and subsequent fluorouracil, leucov

37 past 15 years because of improved access to first-line treatment and vector control.

38 t loss as core treatments, topical NSAIDs as first-line treatments and oral NSAIDs and intra-articula

39 Roughly 60% of patients respond poorly to first-line treatments and thus new therapeutic strategie

40 c reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and s

41 problem, and antidepressants are the current first-line treatment approach.

42 istant strains of Mycobacterium tuberculosis First-line treatments are anchored by two antibiotics, r

43 omy should be offered endovascular repair as first-line treatment at experienced vascular centers.

44 s of pathogens among which the resistance to first-line treatments, attributed in part to mutations i

45 t of appendiceal abscess is recommended as a first line treatment, but some controversy exists.

46 fection for which ceftriaxone is the current first-line treatment, but antimicrobial resistance is em

47 n-containing regimens could be an option for first-line treatment, but its efficacy should be evaluat

48 Maintenance opioid agonist therapy is the first-line treatment, but many patients do not stop usin

49 Corticosteroids still constitute the first-line treatment, but new treatment strategies, incl

50 permeable GABAA receptors, are indicated as first-line treatment, but this is ineffective in many ca

51 he purpose of this article was to inform the first-line treatment choice between cognitive-behavioral

52 e, and prednisone (CHOP) remain the standard first-line treatment choice for systemic ALCL, but in ma

53 capacity than patients who have responded to first-line treatment (Cohen's d=0.9191 (whole striatum),

54 First-line treatment consisted of either an 8-week alter

55 First-line treatment consisted of steroids alone (27.6%)

56 during at least 6 months of treatment with a first-line treatment containing an NNRTI and two NRTIs,

57 haracterized by poor rates of remission with first-line treatments, contributing to the chronic illne

58 tered to 92% of patients, mostly as standard first-line treatment corresponding to stage; 8% of patie

59 Antimonial compounds are used as first-line treatment drugs, but their toxicity, which ca

60 The addition of bevacizumab to ET in first-line treatment failed to produce a statistically s

61 r incidence of CMV viremia, a higher rate of first-line treatment failure and a longer time to virus

62 n is significantly predictive (P = .0009) of first-line treatment failure and symptomatic relapse and

63 dults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boos

64 Methylphenidate (MPH) is a first line treatment for ADHD and is also misused as a p

65 Systemic chemotherapy is the first line treatment for patients with unresectable panc

66 neumatic retinopexy should be considered the first line treatment for RRD in patients fulfilling Pneu

67 Imatinib was the first-line treatment for 111 patients, nilotinib for sev

68 roup of beta-lactam antibiotics that are the first-line treatment for a range of infections.

69 Methylphenidate is a first-line treatment for ADHD, however no previous meta-

70 FOLFIRI as first-line treatment for advanced gastric and EGJ cancer

71 citabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tis

72 did not improve progression-free survival as first-line treatment for advanced ovarian cancer.

73 or without (CHOP) rituximab is the standard first-line treatment for aggressive non-Hodgkin lymphoma

74 ts to compare alectinib with crizotinib as a first-line treatment for ALK-positive non-small-cell lun

75 it of 600 mg of alectinib twice per day as a first-line treatment for ALK-positive non-small-cell lun

76 Epinephrine is the first-line treatment for anaphylaxis.

77 Exposure therapy is a first-line treatment for anxiety disorders but remains i

78 ry in experienced hands is safe and feasible first-line treatment for appendiceal abscess.

79 Although corticosteroid is the first-line treatment for asthma, a subset of patients is

80 orally administered methylphenidate (MPH), a first-line treatment for attention deficit hyperactivity

81 Lithium (Li) is a first-line treatment for bipolar disorder (BD).

82 Although lithium preparations remain first-line treatment for bipolar disorder, risk for deve

83 ibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas

84 d brief therapy and might be considered as a first-line treatment for children with anxiety problems.

85 omnia (CBT-i) is now commonly recommended as first-line treatment for chronic insomnia.

86 Fluoropyrimidines are the first-line treatment for colorectal cancer, but their ef

87 r of the extracorporeal dialysis circuit) as first-line treatment for continuous kidney replacement t

88 ds the use of psychological interventions as first-line treatment for depression in low-income and mi

89 ents who experienced relapse after receiving first-line treatment for disseminated disease.

90 colchicine should be probably regarded as a first-line treatment for either acute or recurrent peric

91 ide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL.

92 hemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but d

93 Temozolomide (TMZ) is first-line treatment for gliomas and recurrent brain met

94 Gentamicin is not appropriate as first-line treatment for gonorrhoea but remains potentia

95 ernative to ceftriaxone plus azithromycin as first-line treatment for gonorrhoea.

96 d combination therapy has been approved as a first-line treatment for head and neck squamous cell car

97 iptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dos

98 was the World Health Organization preferred first-line treatment for human immunodeficiency virus ty

99 First-line treatment for Hymenoptera sting anaphylaxis i

100 recommended by international consensus as a first-line treatment for idiopathic multicentric Castlem

101 Corticosteroids are still the standard first-line treatment for immune thrombocytopenic purpura

102 havioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia; a key component of th

103 upervised exercise therapy is recommended as first-line treatment for intermittent claudication by re

104 Supervised exercise is recommended as a first-line treatment for intermittent claudication.

105 consider with their patients when selecting first-line treatment for locally advanced or metastatic

106 For many years, first-line treatment for locally advanced or metastatic

107 is percutaneous minimally invasive therapy a first-line treatment for many patients at extreme risk f

108 hout tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma

109 f multiple plastic stents in parallel is the first-line treatment for most benign biliary strictures;

110 Although fluid restriction remains the first-line treatment for most forms of chronic hyponatre

111 TION: Doxorubicin should remain the standard first-line treatment for most patients with advanced sof

112 nd ritual prevention (EX/RP) is an effective first-line treatment for obsessive-compulsive disorder (

113 laser trabeculoplasty should be offered as a first-line treatment for open angle glaucoma and ocular

114 es to prevent or treat heart failure are the first-line treatment for patients with DCM.

115 ine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor

116 everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive adv

117 uzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal g

118 the stones outlet, can be considered as the first-line treatment for patients with large and multipl

119 Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colore

120 Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colore

121 Regarding first-line treatment for patients with non-squamous cell

122 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untrea

123 pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or met

124 Chloroquine is the first-line treatment for Plasmodium vivax malaria in mos

125 Exposure-based psychotherapy is a first-line treatment for posttraumatic stress disorder (

126 ormulations of topical azole antifungals are first-line treatment for pregnant women, oral fluconazol

127 Ursodeoxycholic acid, the standard first-line treatment for primary biliary cholangitis, is

128 serotonin reuptake inhibitors (SSRIs) are a first-line treatment for PTSD, but treatment mechanisms

129 procedural complications has now become the first-line treatment for PVL.

130 latinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC a

131 inib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC).

132 Oral glucocorticoids are the standard first-line treatment for sarcoidosis.

133 ased chemotherapeutic drug, which is used as first-line treatment for some types of colorectal carcin

134 First-line treatment for symptomatic OSA is continuous p

135 rgical resection should be considered as the first-line treatment for these patients.

136 TAE could be recommended as first-line treatment for these patients.

137 yrimidine chemotherapy is not recommended as first-line treatment for this patient population.

138 was more common among those who discontinued first-line treatment for this reason.

139 tolerated oral agent that is a commonly used first-line treatment for type 2 diabetes, has become the

140 Metformin is the first-line treatment for type 2 diabetes.

141 Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.

142 artemisinin-based combination therapy as the first-line treatment for uncomplicated Plasmodium falcip

143 ed corticosteroids (ICSs) are widely used as first-line treatment for various chronic respiratory ill

144 rect oral anticoagulants (DOACs) have become first-line treatment for venous thrombotic events.

145 e exercise or psychological interventions as first-line treatments for CRF.

146 Because these are common first-line treatments for faecal incontinence, clinician

147 z-based combinations have been considered as first-line treatments for HIV-1 in resource-limited sett

148 First-line treatments for idiopathic multicentric Castle

149 Many first-line treatments for neglected tropical diseases id

150 ccelerated fibrosarcoma (RAF) inhibitors are first-line treatments for patients harboring V600E/K mut

151 sone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfa

152 del(17p) and relapsed CLL from 2014, and for first-line treatment from 2016 onward.

153 Currently, the first line treatment, gemcitabine, is only effective in

154 ltivariate analysis, ineffective response to first-line treatment (hazard ratio [HR]: 20.6; P = 0.01)

155 previous trastuzumab treatment (adjuvant vs first-line treatment), hormone receptor status (oestroge

156 Metronidazole is the first-line treatment; however, treatment failure and rec

157 ole for specific indications but remains the first line treatment in most units.

158 bitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR

159 Cladribine was used as the first-line treatment in 9 patients and as later-line tre

160 first such study to address the question of first-line treatment in a randomized trial.

161 Lithium is a first-line treatment in bipolar disorder, but individual

162 LY2828360 may be useful as a first-line treatment in chemotherapy-induced neuropathic

163 mab vedotin combined with pembrolizumab as a first-line treatment in February 2020 for cisplatin-inel

164 fficult decision given that these agents are first-line treatment in many guidelines.

165 inhibitor bevacizumab (BVZ) is approved as a first-line treatment in metastatic colorectal cancer (mC

166 of adding IMA901 to sunitinib, the standard first-line treatment in metastatic renal cell carcinoma

167 trong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic a

168 portant treatment option and can even be the first-line treatment in patients with acromegaly who wil

169 ibitor that blocks PD-1 and is approved as a first-line treatment in patients with advanced metastati

170 tologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-ce

171 Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear

172 e of ATRA plus arsenic trioxide as preferred first-line treatment in patients with low- or intermedia

173 utcome in relation to prognostic factors and first-line treatment in patients with MCL in a populatio

174 overall survival when added to sunitinib as first-line treatment in patients with metastatic renal c

175 L who had received Hodgkin lymphoma-directed first-line treatment in randomized GHSG trial protocols

176 These findings support the use of PMC as first-line treatment in selected patients with calcific

177 t GalT-KO skin grafts could provide an early first-line treatment in the management of severe burns t

178 ges, n = 144) who had received stage-adapted first-line treatment in the randomized GHSG HD7 to HD15

179 to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population.

180 ctures; bisphosphonates are commonly used as first-line treatment in women who do not have contraindi

181 to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia.

182 First line treatment is radiotherapy, which many patient

183 The only approved first-line treatment is the multi-tyrosine kinase inhibi

184 liver transplantation cannot be considered a first-line treatment, it is a valid therapeutic option i

185 ents started CAZ-AVI salvage therapy after a first-line treatment (median, 7 days) with other antimic

186 tastatic cancers that were not responding to first-line treatments met study criteria.

187 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoria

188 -directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has

189 fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC.

190 ectedin plus doxorubicin with doxorubicin as first-line treatment of advanced STS patients.

191 t show superiority over doxorubicin alone as first-line treatment of advanced STS.

192 ety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-ce

193 ipilimumab was effective and tolerable as a first-line treatment of advanced/metastatic NSCLC.

194 chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutatio

195 nd CsA appeared to be safe and effective for first-line treatment of cGVHD.

196 y with methylphenidate (MPH) seems to be the first-line treatment of choice in adults with attention-

197 bizumab, aflibercept, laser, and sham in the first-line treatment of diabetic macular edema (DME) to

198 of patients with relapse after risk-adapted first-line treatment of early-stage, favorable, classic

199 evacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxici

200 kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small

201 -etoposide as a new standard of care for the first-line treatment of ES-SCLC.

202 erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced

203 lus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric c

204 sfer inhibitors (InSTIs) are recommended for first-line treatment of HIV-infection.

205 In first-line treatment of Hodgkin lymphoma (HL), Deauville

206 nation with an AI compared with AI alone for first-line treatment of hormone receptor-positive, human

207 trospective, SBRT appears to be a reasonable first-line treatment of inoperable, larger HCC.

208 tients of any age who received FOLFIRINOX as first-line treatment of locally advanced pancreatic canc

209 (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced squamous cell c

210 inhibitors (TKIs), such as erlotinib, as the first-line treatment of lung cancers.

211 nd safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (

212 In the first-line treatment of mCRC, patients with RAS wild-typ

213 ne, cyclophosphamide, and rituximab (FCR) is first-line treatment of medically fit chronic lymphocyti

214 Dietary advice is the cornerstone in first-line treatment of metabolic diseases.

215 ssed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzu

216 ination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung c

217 mbrolizumab to standard chemotherapy for the first-line treatment of metastatic triple-negative breas

218 of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improv

219 Platinum-based chemotherapy for first-line treatment of metastatic urothelial cancer is

220 In the first-line treatment of metastatic urothelial carcinoma,

221 delines recommend biologics as an option for first-line treatment of moderate to severe plaque psoria

222 bevacizumab (atezo + bev) may be offered as first-line treatment of most patients with advanced HCC,

223 tatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differen

224 chemotherapy with and without necitumumab as first-line treatment of mSqCLC, to evaluate the costs an

225 l benefit when combined with chemotherapy as first-line treatment of non-small-cell lung cancer.

226 R tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-muta

227 rs sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Chil

228 limumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma

229 palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestroge

230 l compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-posi

231 progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-posi

232 free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (

233 mab plus chemotherapy versus chemotherapy as first-line treatment of patients with stage IV non-squam

234 The main component of the first-line treatment of pemphigus vulgaris is high doses

235 icity, the withdrawal of chloroquine (CQ) as first-line treatment of Plasmodium falciparum infections

236 sinin-based combination therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria.

237 tion cephalosporins have been considered the first-line treatment of SBP.

238 First-line treatment of stage IA NLPHL usually consists

239 zopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or

240 aromatase inhibitor, a standard of care for first-line treatment of these patients.

241 s platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial ca

242 metrexed could be an effective and tolerable first-line treatment option for patients with advanced n

243 n R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent a

244 s support atezolizumab plus bevacizumab as a first-line treatment option for selected patients with a

245 gh-risk features and provides an alternative first-line treatment option for these patients.

246 -small-cell lung cancer and represents a new first-line treatment option for this disease.

247 Afatinib should be considered as a first-line treatment option for this patient population.

248 e witnessed checkpoint inhibition becoming a first-line treatment option with US Food and Drug Admini

249 acin-based sequential quadruple therapies as first-line treatment options and determine factors assoc

250 ility of remission or treatment failure with first-line treatment options for major depression.

251 The first-line treatment options, pentamidine and nifurtimox

252 Cladribine therapy in first-line treatment or later.

253 apy may be considered in cases of failure of first-line treatments or to modify the natural course of

254 ezolizumab to platinum-based chemotherapy as first-line treatment prolonged progression-free survival

255 rawn and recommendations made for diagnosis, first-line treatment, radiotherapy, and post-treatment c

256 ational guidelines recommend azithromycin as first-line treatment, rapid spread of macrolide resistan

257 n-based combination therapies (ACTs) are the first-line treatment recommended by the WHO to treat Pla

258 We observed a high prevalence of AMR to first-line treatments recommended by WHO, and more than

259 crobials that were previously recommended as first-line treatment regimens, and current treatment opt

260 ines recommend bismuth quadruple therapy for first-line treatment, replacing clarithromycin-based tri

261 te survival in castrate conditions-mimicking first line treatment resistance with hormonal therapies.

262 nical trial of aripiprazole augmentation for first-line treatment-resistant late-life depression (Inc

263 t randomized study strongly suggests that in first-line treatment, rituximab combined with steroids i

264 correlate with symptom change following two first-line treatments-selective serotonin reuptake inhib

265 Re-treatment options are available, but first-line treatment strategies should be optimized to e

266 ought to evaluate the effect of BDex+AA as a first-line treatment strategy on mortality in patients w

267 the use of levofloxacin/moxifloxacin in the first-line treatment; this could be due to the varied re

268 The policy option to change the standard first-line treatment to a boosted protease inhibitor reg

269 Azathioprine is used as a first-line treatment to prevent relapses of neuromyeliti

270 an noninvasive ventilation be offered as the first-line treatment to stable ambulatory patients with

271 Data on baseline characteristics, first-line treatment, treatment response, and survival o

272 First-line treatment was based on relapse site and exten

273 After relapse, first-line treatment was chemotherapy for 95 (58.6%) and

274 bance (2D); 3) in patients refractory to the first-line treatments, we suggest incremental doses of h

275 kin lymphoma who had responded completely to first-line treatment were randomly assigned (1:1) to fol

276 im complete response rates to anti-PD1 based first-line treatment were recently reported for patients

277 preferred to extended-release naltrexone as first-line treatment when both options are clinically ap

278 Hydroxyurea and interferon may be used as first-line treatments, whereas busulfan is reserved for

279 Standard first-line treatment, which includes surgery followed by

280 who receive platinum-doublet chemotherapy as first-line treatment, which often includes a taxane, are

281 Oral propranolol is now the first-line treatment, which should be administered as ea

282 with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination con

283 First-line treatment with a vascular endothelial growth

284 jor congenital malformations associated with first-line treatment with an artemisinin derivative comp

285 Following first-line treatment with atezo + bev, and until better

286 oes not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy

287 f patients with severe acute GVHD respond to first-line treatment with corticosteroids and, for sever

288 First-line treatment with dabrafenib plus trametinib led

289 hemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab tha

290 At present, first-line treatment with EGFR TKIs (gefitinib, erlotini

291 First-line treatment with either first-generation antips

292 aclitaxel should be offered to patients with first-line treatment with FOLFIRINOX, an ECOG PS 0 to 1,

293 rinotecan should be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxe

294 First-line treatment with high-dose liposomal amphoteric

295 ents identified at the time of resistance to first-line treatment with imatinib at six institutions (

296 d were screened at the time of resistance to first-line treatment with imatinib.

297 These results continue to support the first-line treatment with pembrolizumab plus axitinib as

298 phoma not otherwise specified) that received first-line treatment with R-CHOP or CHOP.

299 y cholangitis have an incomplete response to first-line treatment with ursodeoxycholic acid.

300 owledge, the effectiveness of rituximab as a first-line treatment without systemic corticosteroids ha